Ikena Oncology Approves Merger and Reverse Stock Split

The latest update is out from Ikena Oncology ( (IKNA) ).

At the annual meeting on July 15, 2025, Ikena Oncology‘s stockholders approved several key proposals, including a merger with Inmagene Biopharmaceuticals and a 1-for-12 reverse stock split. The merger will result in the combined company, ImageneBio, Inc., trading on Nasdaq under the ticker ‘IMA’. The reverse stock split will significantly reduce the number of outstanding shares, potentially impacting stockholder value and market perception. These changes are expected to be effective by the end of July, subject to closing conditions.

The most recent analyst rating on (IKNA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Ikena Oncology stock, see the IKNA Stock Forecast page.

Spark’s Take on IKNA Stock

According to Spark, TipRanks’ AI Analyst, IKNA is a Neutral.

Ikena Oncology’s overall stock score of 41.2 reflects significant challenges in financial performance, including declining revenues and negative cash flow, which weigh heavily on the score. Technical analysis shows lackluster momentum, while the valuation is unattractive due to negative earnings. Improvements in revenue generation and profitability are crucial for a better financial outlook.

To see Spark’s full report on IKNA stock, click here.

More about Ikena Oncology

Ikena Oncology is a company focused on developing differentiated therapies targeting cancer growth, spread, and therapeutic resistance. The company aims to leverage its institutional knowledge and tools to efficiently develop the right drug for the right patient.

Average Trading Volume: 103,343

Technical Sentiment Signal: Sell

Current Market Cap: $66.6M

See more insights into IKNA stock on TipRanks’ Stock Analysis page.